A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children

Acta Med Okayama. 2020 Feb;74(1):89-94. doi: 10.18926/AMO/57959.

Abstract

No standard treatment for relapsed or refractory anaplastic large-cell lymphoma (ALCL) has been established. This study is a multicenter, open-label trial to examine the effectiveness and safety of transplantation with reduced-intensity conditioning (RIC) for patients under 20 years old with relapsed or refractory ALCL. We defined RIC as the administration of fludarabine (30 mg/m2/day) for five days plus melphalan (70 mg/m2/day) for two days and total body irradiation at 4 Gy, followed by allogeneic hematopoietic stem cell transplantation.

Keywords: anaplastic large-cell lymphoma; fludarabine; melphalan; relapsed/refractory; total body irradiation.

Publication types

  • Clinical Trial Protocol

MeSH terms

  • Adolescent
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols
  • Child
  • Clinical Trials as Topic
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Lymphoma, Large-Cell, Anaplastic / therapy*
  • Melphalan / therapeutic use
  • Transplantation Conditioning / methods*
  • Vidarabine / analogs & derivatives
  • Vidarabine / therapeutic use

Substances

  • Antineoplastic Agents
  • Vidarabine
  • fludarabine
  • Melphalan